OncoMatch/Clinical Trials/NCT04115306
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Is NCT04115306 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including PMD-026 and fulvestrant for metastatic breast cancer.
Treatment: PMD-026 · fulvestrant — The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: RPS6KA3 positive
RSK2 positive from available archival or fresh tumor tissue (FFPE)
Required: ESR1 wild-type
ESR1 wild type
Disease stage
Metastatic disease required
Prior therapy
Must have received: endocrine therapy — metastatic or adjuvant
Must have received: cdk4/6 inhibitor — locally advanced or metastatic
Cannot have received: chemotherapy
Lab requirements
Blood counts
adequate hematologic function as assessed by laboratory parameters
Kidney function
adequate renal function as assessed by laboratory parameters
Liver function
adequate hepatic function as assessed by laboratory parameters
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- City of Hope · Duarte, California
- City of Hope Orange County, Lennar · Irvine, California
- University of California, Los Angeles (UCLA) · Los Angeles, California
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify